• Wondering whether Protagonist Therapeutics at around US$105.55 still offers value, or if most of the opportunity is already reflected in the price.
• The stock has posted returns of 0.1% over the past week, 7.1% over 30 days, 21.1% year to date and 128.7% over the last year, which may have shifted how investors think about both its potential and its risks.
• Recent news coverage has focused on Protagonist Therapeutics as a higher profile biotech name, with attention centered on its pipeline progress and regulatory milestones. This context helps frame how the stock has performed over the past 1 year and 3 years and how that performance may relate to growing investor interest.
• Protagonist Therapeutics holds a value score of 3/6, and the sections that follow walk through different valuation approaches before finishing with a broader way to think about what that score may mean for you.

Approach 1: Protagonist Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, aiming to arrive at an estimate of what the business might be worth per share right now.

For Protagonist Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow stands at about $57.37 million. Analysts provide free cash flow estimates out to 2029, and Simply Wall St extrapolates beyond that to 2035. Within these projections, free cash flow is expected to reach $624 million in 2030, with interim annual figures such as $326 million in 2026 and $414 million in 2029, all in $.

Discounting these projected cash flows back to today produces an estimated intrinsic value of about $357.22 per share. Compared with the recent share price of about $105.55, the DCF output implies the stock is 70.5% undervalued under these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Protagonist Therapeutics is undervalued by 70.5%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Protagonist Therapeutics Price vs Book

For companies where current earnings and revenue are less useful guides, the price to book, or P/B, ratio can help you think about what the market is paying relative to the net assets on the balance sheet. It is often used for research stage biotechs where traditional profit based metrics like P/E are less meaningful.

A “fair” P/B ratio usually reflects how investors weigh growth potential against risks. Higher expected growth or stronger assets can support a higher P/B, while greater uncertainty can justify a lower one. Comparing only with simple benchmarks can miss these nuances.

Protagonist Therapeutics currently trades on a P/B of about 10.96x. That sits well above the Biotechs industry average of about 2.45x and below the peer group average of around 19.81x. Simply Wall St also uses a proprietary “Fair Ratio” for P/B that aims to indicate what multiple might be appropriate given factors such as earnings growth, profit margins, size and risk profile, rather than just lining the stock up against broad industry or peer averages.

Because the Fair Ratio figure is not provided here, there is not enough information to conclude whether the current 10.96x P/B suggests Protagonist Therapeutics is overvalued, undervalued or about right.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Protagonist Therapeutics Narrative

Earlier it was mentioned that there is an even better way to think about valuation. Narratives give you that by letting you connect your view of Protagonist Therapeutics, including your expectations for future revenue, earnings and margins, to a financial forecast, a fair value estimate and a clear comparison with the current price. All of this is available within an easy tool on Simply Wall St’s Community page that updates when new information like news or earnings arrives. One investor might build a Narrative that sees Protagonist Therapeutics as attractive at a much higher fair value, while another might set a much lower fair value based on a more cautious outlook. Both can quickly see how their story stacks up against today’s share price and decide what that means for their own investment decisions.

Do you think there's more to the story for Protagonist Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.